Shared on 21 Oct 25
Fair value Increased 12%Analysts have raised their price target for Aker BioMarine from NOK 61.60 to NOK 69.22, citing improved profit margin expectations as a key factor that supports the revised valuation. What's in the News Aker BioMarine ASA has been dropped from the S&P Global BMI Index (Key Developments) The company has secured new business with a customer for the supply of Superba Krill Oil.
Shared on 23 Apr 25
Fair value Decreased 12%AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.1%.
Shared on 17 Apr 25
Fair value Increased 1.83%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Decreased 13%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Decreased 1.29%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Increased 0.34%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 12 Mar 25
Fair value Increased 8.05%AnalystConsensusTarget has decreased revenue growth from 14.5% to 10.9%, decreased profit margin from 12.6% to 10.0%, increased future PE multiple from 12.4x to 22.2x and increased shares outstanding growth rate from -0.1% to 0.0%.